Isosorbide Dinitrate and Nitroglycerin Therapy

Introduction to Nitrates

• The American College of Cardiology states that nitroglycerin is the only nitrate formulation available for intravenous use in the United States 1
• The American College of Cardiology recommends using nitroglycerin instead of ISDN for intravenous nitrate therapy 1

Nitroglycerin IV Infusion

• Nitroglycerin has a very short half-life of only several minutes, making it suitable for IV titration, as stated by the American College of Cardiology 1
• Standard preparation involves diluting nitroglycerin in D5W or normal saline using non-PVC tubing, according to the European Heart Journal 2
• Typical starting dose is 5-10 mcg/min, titrated upward by 5-10 mcg/min every 3-5 minutes based on blood pressure and symptom response, as recommended by the American College of Cardiology 1

Critical Monitoring Requirements

• The American College of Cardiology advises careful monitoring of blood pressure to avoid inadvertent systemic hypotension, which can cause reflex tachycardia and worsen myocardial ischemia 1
• The American College of Cardiology recommends exercising extreme caution in patients with inferior wall MI due to frequent association with right ventricular infarction—these patients depend on adequate RV preload and can experience profound hypotension 1

Oral ISDN Dosing

• The European Journal of Heart Failure and the European Heart Journal recommend a starting dose of 20 mg three times daily for oral ISDN therapy 3, 4
• The European Journal of Heart Failure and the European Heart Journal suggest a target dose of 40 mg three times daily after 2-4 weeks if tolerated 3, 4

Essential Tolerance Prevention

• The European Heart Journal advises providing a nitrate-free interval of at least 10-14 hours daily to prevent tolerance development 2
• Tolerance typically develops after 24 hours of continuous therapy, according to the European Heart Journal and other sources 2

ISDN Drip Protocol Considerations

Critical Monitoring and Contraindications

• The American College of Cardiology recommends avoiding systolic BP <90 mm Hg or >30 mm Hg below baseline when using ISDN IV, and in previously normotensive patients, do not titrate systolic BP below 110 mm Hg, and in hypertensive patients, do not reduce mean arterial pressure by >25% 5
• Contraindications for ISDN IV use include sildenafil use within 24 hours, tadalafil use within 48 hours, initial systolic BP <90 mm Hg, and marked bradycardia or tachycardia 5

Preferred Alternative: Nitroglycerin IV Protocol

• The American College of Cardiology recommends a starting dose of 5-10 mcg/min for nitroglycerin IV, with titration increases of 10 mcg/min every 3-5 minutes until symptom relief or BP response, and a maximum dose typically of 200 mcg/min 5

Nitrate Therapy in Acute Myocardial Infarction

Introduction to Nitrate Therapy

• The American College of Cardiology recommends intravenous nitroglycerin as the preferred nitrate for acute myocardial infarction due to its superior titratability and short half-life of several minutes 6, 7

Pharmacokinetic Differences

• ISDN undergoes extensive hepatic metabolism to two active metabolites, with a half-life of 40-90 minutes and variable bioavailability due to first-pass metabolism, as noted by the American College of Cardiology 8, 6, 7
• ISMN is the principal active metabolite of ISDN, does not undergo hepatic metabolism, achieves 100% bioavailability after oral dosing, and has a longer half-life of 4-5 hours, according to the American College of Cardiology 8, 6, 7
• Nitroglycerin IV has a half-life of only several minutes, making it ideal for acute titration and the only nitrate formulated for intravenous use in the United States, as recommended by the American College of Cardiology 6, 7

Evidence for Nitrate Use in Acute MI

• The ISIS-4 trial, involving 58,050 patients, compared controlled-release oral ISMN with placebo and found only a small, nonsignificant reduction in 35-day mortality, with a strength of evidence considered modest at best 8, 6
• Meta-analysis of all randomized trials shows a small but statistically significant relative mortality reduction of 5.5% ± 2.6% (p=0.003), representing approximately 4 lives saved per 1000 treated, as reported by the American College of Cardiology 8, 6
• The totality of evidence does not support routine long-term nitrate therapy in uncomplicated acute MI, according to the American College of Cardiology 8, 6

Recommended Approach for Acute MI

• The American College of Cardiology recommends using IV nitroglycerin for the first 24-48 hours in patients with acute MI who have recurrent ischemia, congestive heart failure, or hypertension requiring management 8, 6
• Transition to oral or topical nitrates is recommended only in patients with CHF and large transmural MIs, as suggested by the American College of Cardiology 8, 6

Critical Safety Considerations

• The American College of Cardiology advises exercising extreme caution in inferior wall MI because of frequent association with right ventricular infarction, as patients depend on adequate RV preload and can experience profound hypotension during nitrate administration 6, 7
• Hypotension management with leg elevation, rapid fluid administration, and atropine are appropriate interventions, as recommended by the American College of Cardiology 8, 6

ISDN Drip Administration Guidelines

Introduction to ISDN Administration

• The European Society of Cardiology recommends slow titration with frequent blood pressure monitoring to avoid large drops in systolic blood pressure when administering ISDN intravenously 9, 10
• The European Society of Cardiology suggests that an arterial line is not routinely required but facilitates titration in patients with borderline pressures 9, 10

Critical Blood Pressure Parameters

• The European Society of Cardiology recommends use of ISDN when systolic blood pressure is greater than 110 mmHg 9, 10
• The European Society of Cardiology recommends use of ISDN with extreme caution when systolic blood pressure is between 90-110 mmHg 9, 10
• The European Society of Cardiology states that a systolic blood pressure less than 90 mmHg is an absolute contraindication for ISDN use 9, 10

Clinical Context for Use

• The European Society of Cardiology recommends ISDN for acute heart failure with systolic blood pressure greater than 110 mmHg, as it decreases left and right heart filling pressures, systemic vascular resistance, and improves dyspnea 9, 10

Tolerance Development

• The European Society of Cardiology notes that tachyphylaxis is common after 24-48 hours of continuous ISDN therapy, necessitating incremental dosing 9, 10